Literature DB >> 27428055

Generic Drug Approvals Since the 1984 Hatch-Waxman Act.

Ravi Gupta1, Aaron S Kesselheim2, Nicholas Downing3, Jeremy Greene4, Joseph S Ross5.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27428055     DOI： 10.1001/jamainternmed.2016.3411

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN： 2168-6106            Impact factor:   21.873


× No keyword cloud information.
  9 in total

1.  Possible Insufficiency of Generic Price Competition to Contain Prices for Orally Administered Anticancer Therapies.

Authors:  Ashley L Cole; Hanna K Sanoff; Stacie B Dusetzina
Journal:  JAMA Intern Med       Date:  2017-11-01       Impact factor: 21.873

2.  The Impact of Off-Patent Drug Acquisitions on Prices.

Authors:  Ravi Gupta; Alexis Henkel; Howard P Forman; Joseph S Ross
Journal:  J Gen Intern Med       Date:  2018-07       Impact factor: 5.128

3.  Generic Drugs in the United States: Policies to Address Pricing and Competition.

Authors:  Ravi Gupta; Nilay D Shah; Joseph S Ross
Journal:  Clin Pharmacol Ther       Date:  2019-01-10       Impact factor: 6.875

Review 4.  The high price of anticancer drugs: origins, implications, barriers, solutions.

Authors:  Vinay Prasad; Kevin De Jesús; Sham Mailankody
Journal:  Nat Rev Clin Oncol       Date:  2017-03-14       Impact factor: 66.675

5.  Value-based drug pricing in the Biden era: Opportunities and prospects.

Authors:  Peter J Neumann; Daniel A Ollendorf; Joshua T Cohen
Journal:  Health Serv Res       Date:  2021-06-03       Impact factor: 3.734

6.  Characteristics of Recent Generic Drug Approvals by the US Food and Drug Administration.

Authors:  Kuo Jiao; Ravi Gupta; Erin Fox; Aaron Kesselheim; Joseph S Ross
Journal:  JAMA Netw Open       Date:  2019-10-02

7.  Characteristics and Price Increases Among Sole-Source, Off-Patent Drugs in the United States, 2008 to 2018.

Authors:  Jonathan D Alpern; Arman A Shahriar; Min Xi; Sunita Thapa; Amy J Kodet; William M Stauffer; Gabriela Vazquez Benitez; Pamala A Pawloski; Steven P Dehmer
Journal:  JAMA Netw Open       Date:  2020-08-03

8.  Affordability and availability of off-patent drugs in the United States-the case for importing from abroad: observational study.

Authors:  Ravi Gupta; Thomas J Bollyky; Matthew Cohen; Joseph S Ross; Aaron S Kesselheim
Journal:  BMJ       Date:  2018-03-19

9.  Barriers to Oncology Biosimilars Uptake in the United States.

Authors:  Chadi Nabhan; Amy Valley; Bruce A Feinberg
Journal:  Oncologist       Date:  2018-07-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.